[FAQ] HepaRG를 Steatosis 연구에 사용한 자료가 있나요? | 고마바이오텍

1. The Impact of Modern Chemotherapy and Chemotherapy-Associated Liver Injuries (CALI) on Liver Function: Value of 99mTc-Labelled-Mebrofenin SPECT-Hepatobiliary Scintigraphy. Truant S, Baillet C, Gnemmi V, Fulbert M, Turpin A, Dardenne S, Leteurtre E, El Amrani M, Dharancy S, Dubuquoy L, Huglo D, Chesné C, Pruvot FR. Ann Surg Oncol. 2021 Apr

 

2. Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds. Legler J, Zalko D, Jourdan F, Jacobs M, Fromenty B, Balaguer P, Bourguet W, Munic Kos V, Nadal A, Beausoleil C, Cristobal S, Remy S, Ermler S, Margiotta-Casaluci L, Griffin JL, Blumberg B, Chesné C, Hoffmann S, Andersson PL, Kamstra JH. Int J Mol Sci. May 2020

 

3. Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Bucher S,  Tête A,  Podechard N,  Liamin M,  Le Guillou D,  Chevanne M,  Coulouarn C,  Imran M,  Gallais I2,  Fernier M,  Hamdaoui Q,  Robin MA,  Sergent O. Sci Rep, Apr 2018

 

4. Metabolomics profiling of steatosis progression in HepaRG® cells using sodium valproate. Cuykx M,  Claes L,  Rodrigues RM,  Vanhaecke T,  Covaci A. Toxicol Lett, Jan 2018

 

5. Regulation of drug metabolism by the interplay of inflammatory signaling, steatosis, and xeno-sensing receptors in HepaRG cells. Tanner N,  Kubik L,  Luckert C,  Thomas M,  Hofmann U,  Zanger UM,  Bohmert L,  Lampen A,  Braeuning A. Drug Metab Dispos, Jan 2018

 

6. Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis. Angrish MM, McQueen CA, Cohen-Hubal E, Bruno M, Ge Y, Chorley BN. Toxicol Sci., Sep 2017

 

7. Bisphenol a induces steatosis in HepaRG cells using a model of perinatal exposure. Bucher S, Jalili P, Le Guillou D, Begriche K, Rondel K, Martinais S, Zalko D, Corlu A, Robin A, Fromenty B. Environmental toxicology, Jun 2016

 

8. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Tolosa L, Gomez-Lechon MJ, Jimenez N, Hervas D, Jover R, Donato MT. toxicology and applied pharmacology, Apr 2016

 

9. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Rogue A, Anthérieu S, Vluggens A, Umbdenstock T, Claude N, Moureyre-Spire C, Weaver R, Guillouzo A. Nature Med, Feb 2014

 

10. Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. Brown M, Compton S, Milburn M, Lawton K, Cheatham B. Obesity , Mar 2013

 

11. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. J Hepatol, Dec 2012

 

12. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Anthérieu S. Toxicology in vitro, May 2012

 

13. CYP4F3B Expression Is Associated with Differentiation of HepaRG Human Hepatocytes and Unaffected by Fatty Acid Overload. Madec S, Cerec V, Plée-Gautier E, Antoun J, Glaise D, Salaun JP, Guguen-Guillouzo C, Corlu A. Drug Metab Dispos, Oct 2011

 

14. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Anthérieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. Hepatology, Jun 2011

 

 

주문정보

견적문의 제품담기

주문정보 - Cat No, PRODUCT, SIZE, 수량 등 항목으로 구성되어있습니다.

	Product	Cat.No.	Size	Maker	Qty	Data Sheet	MSDS

전체보기

추천제품

관련제품

견적문의 제품담기

주문정보 - Cat No, PRODUCT, SIZE, 수량 등 항목으로 구성되어있습니다.

	Product	Cat.No.	Size	Maker	Qty	Data Sheet	MSDS

전체보기

자료

웨비나/Video